Loading
PANOVA-3 is the trial behind the 2026 approval of a wearable electric-field device for pancreatic cancer, the first new approval in locally advanced disease in decades.
PANOVA-3, trial NCT03377491 sponsored by Novocure and reported in 2025, is the trial behind the 2026 approval of Optune Pax, a wearable electric-field device, for unresectable locally advanced pancreatic cancer, the first new approval in that setting in decades. It randomised 571 patients to tumour treating fields plus gemcitabine and nab-paclitaxel or chemotherapy alone, met its primary overall survival endpoint with a modest effect presented at the ASCO 2025 plenary, and also improved pain-free survival, leading to FDA approval in the first quarter of 2026. OnCo links it to pancreatic ductal adenocarcinoma, tumour treating fields, the Optune device record, gemcitabine plus nab-paclitaxel and Novocure. It is a single pivotal trial, and its open-label design and modest effect size are debated, so whether the device changes practice outside trial centres is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
571 enrolled.
95% CI 10.3 to 22.8 · 95% CI 7.4 to 12.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | TTFields + gemcitabine/nab-paclitaxel | 284 | 16.2 months | 0.82 (0.68 to 0.99) | 0.039 | link |
| Gemcitabine/nab-paclitaxel | 287 | 14.2 months | ||||
| Pain-free survival | TTFields + gemcitabine/nab-paclitaxel | - | 15.2 months | 0.74 (0.56 to 0.97) | 0.027 | link |
| Gemcitabine/nab-paclitaxel | - | 9.1 months |
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields), Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants.
Shares Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study, LAP07, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields), Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants.
Shares Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares MPACT, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
Shares LAP07, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.